You will be provided with a reference and some statements. Please determine whether each statement is 'supported', 'unsupported', or 'unknown' with respect to the reference. Please note:
First, assess whether the reference contains any valid content. If the reference contains no valid information, such as a 'page not found' message, then all statements should be considered 'unknown'.
If the reference is valid, for a given statement: if the facts or data it contains can be found entirely or partially within the reference, it is considered 'supported' (data accepts rounding); if all facts and data in the statement cannot be found in the reference, it is considered 'unsupported'.

You should return the result in a JSON list format, where each item in the list contains the statement's index and the judgment result, for example:
[
    {
        "idx": 1,
        "result": "supported"
    },
    {
        "idx": 2,
        "result": "unsupported"
    }
]

Below are the reference and statements:
<reference>
Study Gets to the Heart of Controversial Chelation Therapy | Office for Science and Society - McGill University

This article was first published in The Montreal Gazette. Chelation therapy is the process of removing heavy metals from the body. It can be used to treat a child with lead poisoning or remove excess iron from the blood of someone with thalassemia. What it can’t do is treat heart disease, and the recent TACT2 trial should hopefully put the final nail in the coffin of this idea. Chelation therapy involves the administration of medications that will bind to heavy metals like mercury, lead, arsenic or iron and allow them to be excreted by the body. It can be life saving in certain circumstances, like a child with acute lead poisoning and neurological symptoms. But chelation therapy is marketed far beyond its limited medical scope. Some individuals promote chelation therapy to treat autism under the mistaken notion that mercury exposure causes autism. It doesn’t, but that hasn’t stopped many private clinics from administering this therapy to children. Chelation therapy can be dangerous: In 2005, the U.S. Centers for Disease Control and Prevention identified two cases of children dying during treatment, and the Food and Drug Administration has started to crack down on false claims that chelation can treat autism. Its role in treating cardiovascular disease is equally tenuous. When pressed as to how it would work, proponents claim that chelation removes calcium from the bloodstream, which then prevents atherosclerosis and hardening of the arteries. But atherosclerosis is more complicated than too much calcium, and lowering calcium levels in the blood can be potentially dangerous and lead to fatal arrhythmias. Despite the vague mechanism of action, chelation remained a popular service by alternative practitioners who would sell it as part of some general detox package. Given the lack of benefit, a large randomized trial was commissioned to investigate the issue. The Trial to Assess Chelation Therapy (TACT), published 11 years ago, surprised many by claiming there was indeed a benefit for cardiovascular outcomes. But on closer inspection, there were some issues. In an accompanying editorial published in JAMA, cardiologist Steven Nissen pointed out some of the problems at the time. TACT was primarily conducted not in a hospital or research setting, but in centres described as complementary and alternative medicine sites that already used chelation. Also, the chelation therapy involved not just the chelating agent disodium EDTA, but also high-dose vitamin C, magnesium, the anesthetic procaine and the blood thinner heparin. There was a high dropout rate of 18 per cent in the study. While dropout and loss to followup does happen in clinical trials, it is rare to see it mostly in the placebo group, since it usually happens in those randomized to the treatment who experience side effects. Finally, the researchers did many interim analyses of their study data. Ideally, you should wait until the end of a trial to analyze the data rather than “peeking” at the data halfway through. In practice, some interim analyses are necessary to ensure there is no safety signal or other issue with the study medication. But while one or two interim analyses would be normal, the TACT trial had 11, which is not in keeping with standard practice. The journal editors had a number of concerns with the paper, but ultimately decided to publish it with all those caveats in place. Despite all these concerns about the conduct of the study, the results of TACT were fairly modest, limited to a reduction in the need for future stents, and seemed to be most pronounced only in diabetics. Hence, the TACT2 trial was launched to verify the results of TACT, and its results were recently published. There was no cardiovascular benefit to the 40 weekly intravenous infusions of disodium EDTA and the multivitamin cocktail that accompanied them. Little more needs to be said on the subject of chelation therapy. It is unfortunate that it took more than a decade to refute the initial dubious results of TACT, but I suppose better late than never. @DrLabos

McGill University

Office for Science and Society

Separating Sense from Nonsense

Enter your keywords

Main navigation

Home
Our Articles
Who We Are
Dr. Joe's Books
Events
Our History
Public Lectures
Past Newsletters
Contributor Submission
Photo Gallery: The McGill OSS Separates 25 Years of Separating Sense from Nonsense

Subscribe to the OSS Weekly Newsletter!

Sign-Up Here

Register for the 2026 Trottier Symposium!

Register here

Home

Study Gets to the Heart of Controversial Chelation Therapy

A recent trial refutes earlier results that showed a cardiovascular benefit to the treatment, which involves medications that bind to heavy metals and allow them to be excreted by the body.

Christopher Labos MD, MSc
| 30 Aug 2024
Medical

Add to calendar

Facebook

LinkedIn

Tweet Widget

This article was first published in
The Montreal Gazette.

Chelation therapy is the process of removing heavy metals from the body. It can be used to treat a child with lead poisoning or remove excess iron from the blood of someone with thalassemia. What it can’t do is treat heart disease, and the recent TACT2 trial should hopefully put the final nail in the coffin of this idea.

Chelation therapy involves the administration of medications that will bind to heavy metals like mercury, lead, arsenic or iron and allow them to be excreted by the body. It can be life saving in certain circumstances, like a child with acute lead poisoning and neurological symptoms. But chelation therapy is marketed far beyond its limited medical scope.

Some individuals promote chelation therapy to treat autism under the mistaken notion that mercury exposure causes autism. It doesn’t, but that hasn’t stopped many private clinics from administering this therapy to children. Chelation therapy can be dangerous: In 2005, the U.S. Centers for Disease Control and Prevention identified
two cases
of children dying during treatment, and the Food and Drug Administration has started to crack down on
false claims
that chelation can treat autism.

Its role in treating cardiovascular disease is equally tenuous. When pressed as to how it would work, proponents claim that chelation removes calcium from the bloodstream, which then prevents atherosclerosis and hardening of the arteries. But atherosclerosis is more complicated than too much calcium, and lowering calcium levels in the blood can be potentially dangerous and lead to fatal arrhythmias.

Despite the vague mechanism of action, chelation remained a popular service by alternative practitioners who would sell it as part of some general detox package.

Given the lack of benefit, a large randomized trial was commissioned to investigate the issue. The
Trial to Assess Chelation Therapy (TACT)
, published 11 years ago, surprised many by claiming there was indeed a benefit for cardiovascular outcomes. But on closer inspection, there were some issues.

In an
accompanying editorial
published in JAMA, cardiologist Steven Nissen pointed out some of the problems at the time. TACT was primarily conducted not in a hospital or research setting, but in centres described as complementary and alternative medicine sites that already used chelation. Also, the chelation therapy involved not just the chelating agent disodium EDTA, but also high-dose vitamin C, magnesium, the anesthetic procaine and the blood thinner heparin.

There was a high dropout rate of 18 per cent in the study. While dropout and loss to followup does happen in clinical trials, it is rare to see it mostly in the placebo group, since it usually happens in those randomized to the treatment who experience side effects.

Finally, the researchers did many interim analyses of their study data. Ideally, you should wait until the end of a trial to analyze the data rather than “peeking” at the data halfway through. In practice, some interim analyses are necessary to ensure there is no safety signal or other issue with the study medication. But while one or two interim analyses would be normal, the TACT trial had 11, which is not in keeping with standard practice.

The journal editors had a
number of concerns
with the paper, but ultimately decided to publish it with all those caveats in place.

Despite all these concerns about the conduct of the study, the results of TACT were fairly modest, limited to a reduction in the need for future stents, and seemed to be most pronounced only in diabetics.

Hence, the TACT2 trial was launched to verify the results of TACT, and its
results were recently published
. There was no cardiovascular benefit to the 40 weekly intravenous infusions of disodium EDTA and the multivitamin cocktail that accompanied them.

Little more needs to be said on the subject of chelation therapy. It is unfortunate that it took more than a decade to refute the initial dubious results of TACT, but I suppose better late than never.

@DrLabos

Keywords:
chelation therapy
heavy metal
TACT trial
cardiovascular disease
autism

What to read next

The “Don’t Trust Your Doctor” Facebook Videos That Lie to You

11 Sep 2026

Barbie Peptide Merits a Close Look

11 Sep 2026

The Organ That “Proved” That Everything Is Connected

4 Sep 2026

Is Sitting the New Smoking?

3 Sep 2026

Being ‘First’ in Drug Discovery Can Be a Nebulous Honour

28 Aug 2026

Why Did We Turn the EpiPen Into a Nasal Spray?

27 Aug 2026

Back to top

Department and University Information

Office for Science and Society

McGill University

801 Sherbrooke Street West

Montreal, Quebec H3A 0B8

Facebook

YouTube

Instagram

Bluesky

McGill University

Copyright © 2026 McGill University

Accessibility

Cookie notice

Cookie settings

Log in
</reference>

<statements>
1. Over-reliance on non-academic complementary medicine centers for participant enrollment
2. Execution of 11 sequential interim analyses, heightening the risk of false-positive statistical discoveries
</statements>

Begin the assessment now. Output only the JSON list, without any conversational text or explanations.